Utreloxastat

Overview

Utreloxastat (PTC857) is an orally active and blood-brain barrier-permeable 15-lipooxygenase inhibitor. Utreloxastat is a weak inhibitor of CYP1A2 and 2B6 with an IC 50 of >5.3 μM. Utreloxastat reduces oxidative stress and inhibits the consumption of reduced glutathione and ferroptosis . Utreloxastat can be used in the study of neurodegenerative diseases characterized by high levels of oxidative stress and mitochondrial pathology, such as amyotrophic lateral sclerosisc.

Application

Products | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Parkinson's Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > α-synuclein | Products > Signaling Pathways > Cytochrome P450 | Products > Signaling Pathways > Ferroptosis | Products > Signaling Pathways > Lipoxygenase

Product Information

• Catalog No.: HY-132845
• CAS No.: 1213269-96-5
• Molecular Formula: C18H28O2
• Molecular Weight: 276.41
• Purity: 99.32%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 1.25 mg/mL (4.52 mM); Clear solution
• Availability: In-stock

Source

Original product source